Evaluation of an intermittent schedule of dibromodulcitol in breast cancer

D. C. Tormey, G. Falkson, E. Perlin, J. Bull, J. Blom, Marc E Lippman

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Dibromodulcitol was administered orally on Days 1-10 every 3-4 weeks to 29 patients with metastatic breast carcinoma refractory to previous combination chemotherapy. Initial doses between 70 and 280 mg/m 2/day were utilized. The dose was escalated as tolerated in subsequent cycles in individual patients. Hematosuppression was dose-limiting. At doses of <200 mg/m 2/day leukopenia (<1000 cells/mm 3) and thrombocytopenia (<25,000 platelets/mm 3) occurred in one of 28 cycles and two of 27 cycles respectively. In contrast, at doses of ≥200 mg/m 2/day leukopenia and thrombocytopenia occurred in four of 18 cycles and five of 18 cycles respectively. Recovery of leukocytes (>4000 cells/mm 3) and platelets (>100,000 platelets/mm 3) by Day 29 after the start of therapy was also delayed at higher doses. Responses were observed in three of 29 evaluable patients and subjective improvement of osseous disease in one additional patient. A dose of 180 mg/m 2/day x 10 every 28 days is recommended in previously treated patients to avoid severe hematologic side effects.

Original languageEnglish
Pages (from-to)1593-1596
Number of pages4
JournalCancer Treatment Reports
Volume60
Issue number11
StatePublished - Dec 1 1976
Externally publishedYes

Fingerprint

Mitolactol
Appointments and Schedules
Breast Neoplasms
Blood Platelets
Combination Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tormey, D. C., Falkson, G., Perlin, E., Bull, J., Blom, J., & Lippman, M. E. (1976). Evaluation of an intermittent schedule of dibromodulcitol in breast cancer. Cancer Treatment Reports, 60(11), 1593-1596.

Evaluation of an intermittent schedule of dibromodulcitol in breast cancer. / Tormey, D. C.; Falkson, G.; Perlin, E.; Bull, J.; Blom, J.; Lippman, Marc E.

In: Cancer Treatment Reports, Vol. 60, No. 11, 01.12.1976, p. 1593-1596.

Research output: Contribution to journalArticle

Tormey, DC, Falkson, G, Perlin, E, Bull, J, Blom, J & Lippman, ME 1976, 'Evaluation of an intermittent schedule of dibromodulcitol in breast cancer', Cancer Treatment Reports, vol. 60, no. 11, pp. 1593-1596.
Tormey DC, Falkson G, Perlin E, Bull J, Blom J, Lippman ME. Evaluation of an intermittent schedule of dibromodulcitol in breast cancer. Cancer Treatment Reports. 1976 Dec 1;60(11):1593-1596.
Tormey, D. C. ; Falkson, G. ; Perlin, E. ; Bull, J. ; Blom, J. ; Lippman, Marc E. / Evaluation of an intermittent schedule of dibromodulcitol in breast cancer. In: Cancer Treatment Reports. 1976 ; Vol. 60, No. 11. pp. 1593-1596.
@article{183fe2fe897e4e93a095976f17afdea5,
title = "Evaluation of an intermittent schedule of dibromodulcitol in breast cancer",
abstract = "Dibromodulcitol was administered orally on Days 1-10 every 3-4 weeks to 29 patients with metastatic breast carcinoma refractory to previous combination chemotherapy. Initial doses between 70 and 280 mg/m 2/day were utilized. The dose was escalated as tolerated in subsequent cycles in individual patients. Hematosuppression was dose-limiting. At doses of <200 mg/m 2/day leukopenia (<1000 cells/mm 3) and thrombocytopenia (<25,000 platelets/mm 3) occurred in one of 28 cycles and two of 27 cycles respectively. In contrast, at doses of ≥200 mg/m 2/day leukopenia and thrombocytopenia occurred in four of 18 cycles and five of 18 cycles respectively. Recovery of leukocytes (>4000 cells/mm 3) and platelets (>100,000 platelets/mm 3) by Day 29 after the start of therapy was also delayed at higher doses. Responses were observed in three of 29 evaluable patients and subjective improvement of osseous disease in one additional patient. A dose of 180 mg/m 2/day x 10 every 28 days is recommended in previously treated patients to avoid severe hematologic side effects.",
author = "Tormey, {D. C.} and G. Falkson and E. Perlin and J. Bull and J. Blom and Lippman, {Marc E}",
year = "1976",
month = "12",
day = "1",
language = "English",
volume = "60",
pages = "1593--1596",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Evaluation of an intermittent schedule of dibromodulcitol in breast cancer

AU - Tormey, D. C.

AU - Falkson, G.

AU - Perlin, E.

AU - Bull, J.

AU - Blom, J.

AU - Lippman, Marc E

PY - 1976/12/1

Y1 - 1976/12/1

N2 - Dibromodulcitol was administered orally on Days 1-10 every 3-4 weeks to 29 patients with metastatic breast carcinoma refractory to previous combination chemotherapy. Initial doses between 70 and 280 mg/m 2/day were utilized. The dose was escalated as tolerated in subsequent cycles in individual patients. Hematosuppression was dose-limiting. At doses of <200 mg/m 2/day leukopenia (<1000 cells/mm 3) and thrombocytopenia (<25,000 platelets/mm 3) occurred in one of 28 cycles and two of 27 cycles respectively. In contrast, at doses of ≥200 mg/m 2/day leukopenia and thrombocytopenia occurred in four of 18 cycles and five of 18 cycles respectively. Recovery of leukocytes (>4000 cells/mm 3) and platelets (>100,000 platelets/mm 3) by Day 29 after the start of therapy was also delayed at higher doses. Responses were observed in three of 29 evaluable patients and subjective improvement of osseous disease in one additional patient. A dose of 180 mg/m 2/day x 10 every 28 days is recommended in previously treated patients to avoid severe hematologic side effects.

AB - Dibromodulcitol was administered orally on Days 1-10 every 3-4 weeks to 29 patients with metastatic breast carcinoma refractory to previous combination chemotherapy. Initial doses between 70 and 280 mg/m 2/day were utilized. The dose was escalated as tolerated in subsequent cycles in individual patients. Hematosuppression was dose-limiting. At doses of <200 mg/m 2/day leukopenia (<1000 cells/mm 3) and thrombocytopenia (<25,000 platelets/mm 3) occurred in one of 28 cycles and two of 27 cycles respectively. In contrast, at doses of ≥200 mg/m 2/day leukopenia and thrombocytopenia occurred in four of 18 cycles and five of 18 cycles respectively. Recovery of leukocytes (>4000 cells/mm 3) and platelets (>100,000 platelets/mm 3) by Day 29 after the start of therapy was also delayed at higher doses. Responses were observed in three of 29 evaluable patients and subjective improvement of osseous disease in one additional patient. A dose of 180 mg/m 2/day x 10 every 28 days is recommended in previously treated patients to avoid severe hematologic side effects.

UR - http://www.scopus.com/inward/record.url?scp=0017035355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017035355&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 1593

EP - 1596

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 11

ER -